Clinical trials: Stable Coronary Heart Disease (CHD)
Atherosclerosis
SB-480848 In Subjects With Coronary Heart Disease
This trial of SB-480848 in approximately 920 subjects with Coronary Heart Disease (CHD) or CHD-risk equivalent will examine whether SB-480848 produces sustained inhibition of plasma Lp-PLA2 activity, explore the effects of…
- Trial name
- NCT00269048
- Testing
- SB-480848
- Where
- 119 sites in United States, Argentina and 14 more
- Volunteers
- 969 people
- Sponsor
- GlaxoSmithKline
Coronary Heart Disease (CHD)
Single vs. Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Intervention With DCB-only Strategy (KONG-FREEDOM-I)
This investigator-initiated, multicenter, open-label, randomized clinical trial evaluates the safety and efficacy of single antiplatelet therapy (SAPT) utilizing a P2Y12 inhibitor compared to dual antiplatelet therapy (DAPT) in…
- Trial name
- KONG-FREEDOM-I (NCT07587099)
- Testing
- Drug-coated balloon, Single antiplatelet therapy (SAPT), Dual antiplatelet therapy (DAPT)
- Where
- 14 sites in China
- Volunteers
- 2,170 people
- Sponsor
- Gan Lijun
Chronic Stable Angina, Unstable Angina
The Role of Alcohol Consumption in the Aetiology of Different Cardiovascular Disease Phenotypes: a CALIBER Study
The association between alcohol consumption and cardiovascular disease (CVD) has mostly been examined using broad endpoints or cause-specific mortality.
- Conditions
- Chronic Stable Angina, Unstable Angina, Coronary Heart Disease Not Otherwise Specified, Acute Myocardial Infarction
- Trial name
- NCT01864031
- Where
- United Kingdom
- Volunteers
- 2,240,000 people
- Sponsor
- University College, London
Angina Pectoris, Coronary Artery Disease
Effects of Integrated Treatment by Traditional Chinese and Western Medicine in Reducing Cardiovascular Events
Compared with standardized western medical drug therapy, this study is mainly about whether the combination of standardized western medical drug therapy and Chinese medical continued treatment, can further decrease the rate of…
- Conditions
- Angina Pectoris, Coronary Artery Disease, Coronary Disease, Heart Disease
- Trial name
- NCT01715376
- Where
- China
- Volunteers
- 1,042 people, healthy volunteers welcome
- Sponsor
- Changchun University of Chinese Medicine
CHD - Coronary Heart Disease, Angina, Stable
Coronary Microcirculatory and Bioresorbable Vascular Scaffolds
Angina and heart attacks are caused by narrowings in the coronary arteries (blood vessels) supplying the heart. These narrowings can be opened using a balloon and stent (angioplasty).
- Conditions
- CHD - Coronary Heart Disease, Angina, Stable, Myocardial Ischemia
- Trial name
- EMPIRE-BVS (NCT03076476)
- Testing
- Bioresorbable Vascular Scaffolds (BVS), Drug-Eluting Stent (DES) - slow, Drug-Eluting Stent (DES) - standard(std)
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- Papworth Hospital NHS Foundation Trust
Stable Coronary Heart Disease (CHD)
Ticagrelor China Pharmacokinetic/Pharmacodynamic Study
open label, single centre, randomised, Phase IV, pharmacokinetic, pharmacodynamic, and safety study to evaluate single and multiple doses of 45, 60, and 90 mg of ticagrelor in Chinese patients with stable coronary heart disease
- Trial name
- NCT02064985
- Testing
- Inhibition of Platelet Aggregation by "Brilinta"(Ticagrelor)
- Where
- China
- Volunteers
- 61 people
- Sponsor
- AstraZeneca
Coronary Heart Disease (CHD)
Clinical Evidence Based and TCM Phenotype Group Study of Zhilong Huoxue Tongyu Capsule in the Treatment of Stable Angina Pectoris of Coronary Heart Disease (Qi Deficiency and Blood Stasis Syndrome)
This study intends to prove the clinical effect of Zhidong Huoxue Tongyu capsule in the treatment of stable angina pectoris with qi deficiency and blood stasis syndrome from the perspective of TCM syndrome differentiation and…
- Trial name
- NCT06709638
- Testing
- Zhilong Huoxue Tongyu capsule
- Where
- China
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Jiang Hanmei
Arterial Hypertension, CHD - Coronary Heart Disease
Assessment of the Efficacy and Tolerability of the Fixed-dose Combination of Bisoprolol/Perindopril
Study objective - to assess the efficacy, tolerability and adherence of bisoprolol/perindopril FDC in patients with HT and stable CAD in everyday practice.
- Trial name
- STYLE (NCT03730116)
- Testing
- bisoprolol/perindopril FDC
- Where
- Russia
- Volunteers
- 1,909 people
- Sponsor
- Servier Russia
Stable Angina, Coronary Disease
Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina
This study of 402 cases of stable angina subjects who were diagnosed as Coronary Heart Disease (CHD) is a randomized, blank controlled, multi-center clinical study.
- Trial name
- SIGMART (NCT01396395)
- Testing
- Nicorandil, Standard Treatment
- Where
- China
- Volunteers
- 402 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Coronary Heart Disease
Clinical Value and Cost-effectiveness of a Personalized Prevention Program (PPP) in Patients With High Risk Stable CHD
Prospective clinical study with two parts: PART A: a prospective biomarker-based risk screening study in coronary heart disease (CHD) subjects PART B: a nested randomized clinical trial (RCT) in an enriched subpopulation of…
- Trial name
- NCT04433052
- Testing
- personalised prevention program (PPP)
- Where
- 26 sites in Finland, Germany and 4 more
- Volunteers
- 12,000 people
- Sponsor
- Tampere University
Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)
A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease
This multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the potential of dalcetrapib to reduce cardiovascular morbidity and mortality in patients with stable coronary heart disease…
- Trial name
- NCT01516541
- Testing
- Background care, dalcetrapib
- Where
- 241 sites in United States, Australia and 11 more
- Volunteers
- 2,220 people
- Sponsor
- Hoffmann-La Roche